Medication adherence and health-related quality of life among patients with chronic obstructive pulmonary disease

Open access

Abstract

This study evaluated medication adherence and health-related quality of life (HRQoL) of Slovenian patients with chronic obstructive pulmonary disease (COPD) and examined the factors associated with HRQoL. Demographic and therapy information was collected from 65 patients through interviews. The St. George’s Respiratory Questionnaire and the Morisky Medication Adherence Scale were used to evaluate HRQoL and adherence, resp. A multiple linear regression model was used to assess the association between the factors and HRQoL. The mean St. George’s Respiratory Questionnaire score (range 0-100, with higher scores indicating lower HRQoL) was 41.4. COPD affected patients’ daily activities more than their social and psychological functioning. Slightly more than 53 % of the patients were optimally adherent, while 12 % were non-adherent. Patients with lower HRQoL had a larger number of medications for concomitant diseases, experienced COPD exacerbation in the last year, and had less education. No statistically significant correlation was found between medication adherence and HRQoL.

1. Global Initiative for Chronic Obstructive Lung Disease, GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD, GOLD, Barcelona, January 2017; http://goldcopd.org; last access date September 29, 2017.

2. World Health Organization, Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015, WHO, Geneva 2016; http://www.who.int/entity/healthinfo/global_burden_disease/GHE2015_Deaths_Global_2000_2015.xls?ua=1; last access date November 6, 2017.

3. R. D. Restrepo, M. T. Alvarez, L. D. Wittnebel, H. Sorenson, R. Wettstein, D. L. Vines, J. Sikkema-Ortiz, D. D. Gardner and R. L. Wilkins, Medication adherence issues in patients treated for COPD, Int. J. Chron. Obstruct. Pulmon. Dis. 3 (2008) 371−384; https://doi.org/10.2147/COPD.S3036.

4. C. R. Wilson Van Voorhis and B. L. Morgan, Understanding power and rules of thumb for determining sample sizes, Tutor. Quant. Meth. Psychol. 3 (2007) 43−50; https://doi.org/10.20982/tqmp.03.2.p043.

5. The American Thoracic Society, St. George’s Respiratory Questionnaire (SGRQ), New York, June 2016; http://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php; last access date September 29, 2017.

6. D. E. Morisky, A. Ang, M. Krousel-Wood and H. J. Ward, Predictive validity of a medication adherence measure in an outpatient setting, J. Clin. Hypertens. (Greenwich) 10 (2008) 348−354; https://doi.org/10.1111/j.1751-7176.2008.07572.x.

7. M. Krousel-Wood, T. Islam, L. S. Webber, R. N. Re, D. E. Morisky and P. Muntner, New medication adherence scale versus pharmacy fill rates in seniors with hypertension, Am. J. Manag. Care 15 (2009) 59−66.

8. D. E. Morisky and M. R. DiMatteo, Improving the measurement of self-reported medication nonadherence: response to authors, J. Clin. Epidemiol. 64 (2011) 255−257; https://doi.org/10.1016/j.jclinepi.2010.09.002.

9. F. Arpinelli, M. Carone, G. Riccardo and G. Bertolotti, Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature, Multidiscip. Respir. Med. 11 (2016) Article ID 5 (7 pages); https://doi.org/10.1186/s40248-016-0040-9.

10. A. Ekici, E. Bulcun, T. Karakoc, E. Senturk and M. Ekici, Factors associated with quality of life in subjects with stable COPD, Respir. Care 60 (2015) 1585−1591; https://doi.org/10.4187/respcare.03904.

11. M. Ferrer, C. Villasante, J. Alonso, V. Sobradillo, R. Gabriel, G. Vilagut, J. F. Masa, J. L. Viejo, C. A. Jimenez-Ruiz and M. Miravitlles, Interpretation of quality of life scores from the St George’s respiratory questionnaire, Eur. Respir. J. 19 (2002) 405−413; https://doi.org/10.1183/09031936.02.00213202

12. M. Miravitlles, M. Ferrer, A. Pont, R. Zalacain, J. L. Alvarez-Sala, F. Masa, H. Verea, C. Murio, F. Ros and R. Vidal, Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study, Thorax 59 (2004) 387−395; https://doi.org/10.1136/thx.2003.008730.

13. M. Miravitlles, J. B. Soriano, F. Garcia-Rio, L. Munoz, E. Duran-Tauleria, G. Sanchez, V. Sobradillo and J. Ancochea, Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities, Thorax 64 (2009) 863−868; https://doi.org/10.1136/thx.2009.115725.

14. J. G. van Manen, P. J. Bindels, F. W. Dekker, B. J. Bottema, J. S. van der Zee, C. J. Ijzermans and E. Schade, The influence of COPD on health-related quality of life independent of the influence of comorbidity, J. Clin. Epidemiol. 56 (2003) 1177−1184; https://doi.org/10.1016/S0895-4356(03)00208-7.

15. M. R. Boland, J. F. van Boven, A. L. Kruis, N. H. Chavannes, T. van der Molen, L. M. Goossens and M. P. Rutten-van Molken, Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence, Respir. Med. 110 (2016) 34−45; https://doi.org/10.1016/j.rmed.2015.11.008.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 117 117 40
PDF Downloads 52 52 23